Sumitomo Dainippon Pharma Annual Report 2017
8/102

Financial and Non-Financial HighlightsP.11Message from the PresidentP.13Business Model for Value CreationP.09ProfileP.01Snapshot 2016P.03Contents / Editorial PolicyP.07P.29Production and Quality ControlBasic Strategy / Drug Discovery / Intellectual Property / Consideration in clinical studiesResearch & DevelopmentP.19P.27Enhanced Pipeline from In-licensing and AcquisitionsFocusWe strive to enhance our pipeline, which sustains our future business, through new in-licensing, acquisitions, and reevaluating in-house projects.Development PipelineP.23The forward-looking statements in this annual report are based on management’s assumptions and beliefs in light of information available up to the date of publication, and involve both known and unknown risks and uncertainties. Actual financial results and development forecast may differ materially from those presented in this document, being dependent on a number of factors. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.Disclaimer Regarding Forward-Looking StatementsApplicable PeriodThis report is based on the results for fiscal 2016 (April 1, 2016 to March 31, 2017). Some of the activities described were conducted in fiscal 2017.Organizational ScopeThe report covers the 16 companies in the Sumitomo Dainippon Pharma Group (Sumitomo Dainippon Pharma Co., Ltd., and its 15 consolidated subsidiaries). However, environmental performance data in the report are totals for major facilities in Japan only (plants, research laboratories, distribution centers, Osaka Head Office, Tokyo Head Office, branches).• IIRC, International Integrated Reporting Framework• G4 Sustainability Reporting GuidelineEditorial PolicyReference guidelines regarding disclosure on non-financial informationContentsContents / Editorial Policy07Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#8

このブックを見る